Showing 136 Results
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
The drug price-related provisions of the Inflation Reduction Act make the case for including dynamic drug pricing in cost-effectiveness analysis even more compelling.
Michael Pratt named Chief Communications Officer as NPC boosts research and engagement capabilities
NPC announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer.
NPC announced Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC’s Board of Directors for 2021-2022.
NPC joined a group of 14 health care organizations in and around Washington, D.C., in issuing a joint statement making COVID-19 vaccination a condition of returning to work in their respective…
Veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, has been appointed as president and chief executive officer of the National Pharmaceutical Council, effective June 1,…
The American Journal of Managed Care® (AJMC®) and Pharmacy Times® today announced that the National Pharmaceutical Council (NPC) has joined their Strategic Alliance Partnership (SAP) programs.
As interim president and CEO, Dr. Robert Dubois plans to focus on two priorities: continuing to leverage NPC's ongoing evidence-based research, partnerships and education, and preparing for future…
Dan Leonard is leaving as head of the National Pharmaceutical Council, effective Sept. 4.